MXPA03005030A - Juego de reactivos inmunoterapeuticos para el tratamiento de tumores. - Google Patents

Juego de reactivos inmunoterapeuticos para el tratamiento de tumores.

Info

Publication number
MXPA03005030A
MXPA03005030A MXPA03005030A MXPA03005030A MXPA03005030A MX PA03005030 A MXPA03005030 A MX PA03005030A MX PA03005030 A MXPA03005030 A MX PA03005030A MX PA03005030 A MXPA03005030 A MX PA03005030A MX PA03005030 A MXPA03005030 A MX PA03005030A
Authority
MX
Mexico
Prior art keywords
receptors
immunotherapeutic
tumors
ligands
patients
Prior art date
Application number
MXPA03005030A
Other languages
English (en)
Inventor
Ramos Tania Crombet
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of MXPA03005030A publication Critical patent/MXPA03005030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se relaciona con el campo de la inmunologia y mas especificamente con la inmunoterapia del cancer, particularmente con un juego de reactivos inmunoterapeutico y el empleo de combinaciones de dichos reactivos para impedir el crecimiento de celulas tumorales y/o eliminar dichas celulas. Los metodos descritos en la presente invencion se basan en el bloqueo de receptores con actividad de proteinas quinasas en residuos de tirosina (RTK) y de ligados para dichos receptores. Se describen combinaciones inmunoterapeuticas que provocan el bloqueo de receptores RTK y/o sus ligados, mediante la combinacion de inmunoterapia activa y/o pasiva contra los mismos y los procedimientos referidos pueden ser aplicados a pacientes en diferentes estadios clinicos de tumores de origen epitelial que sobre-expresan estos receptores. La combinacion de inmunoterapia activa y pasiva puede ser simultanea o secuencial en dependencia de si el procedimiento terapeutico va a ser utilizado en pacientes con enfermedad avanzada o como terapia adyuvante.
MXPA03005030A 2000-12-08 2001-12-06 Juego de reactivos inmunoterapeuticos para el tratamiento de tumores. MXPA03005030A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20000287A CU22979A1 (es) 2000-12-08 2000-12-08 Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
PCT/CU2001/000012 WO2002045747A1 (es) 2000-12-08 2001-12-06 Combinaciones inmunoterapeuticas para el tratamiento de tumores

Publications (1)

Publication Number Publication Date
MXPA03005030A true MXPA03005030A (es) 2004-09-10

Family

ID=40261022

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005030A MXPA03005030A (es) 2000-12-08 2001-12-06 Juego de reactivos inmunoterapeuticos para el tratamiento de tumores.

Country Status (26)

Country Link
US (2) US20020160014A1 (es)
EP (2) EP2005996A3 (es)
JP (2) JP2005519023A (es)
KR (1) KR20030064416A (es)
CN (1) CN1326566C (es)
AR (1) AR031641A1 (es)
AT (1) ATE403438T1 (es)
AU (2) AU2002221521B2 (es)
BR (1) BR0116010A (es)
CA (1) CA2431199C (es)
CU (1) CU22979A1 (es)
CY (1) CY1108474T1 (es)
DE (1) DE60135248D1 (es)
DK (1) DK1350521T3 (es)
EA (1) EA007381B1 (es)
ES (1) ES2311036T3 (es)
HK (1) HK1073244A1 (es)
MX (1) MXPA03005030A (es)
MY (1) MY138833A (es)
NZ (1) NZ526284A (es)
PE (1) PE20020695A1 (es)
PT (1) PT1350521E (es)
SI (1) SI1350521T1 (es)
UY (1) UY27058A1 (es)
WO (1) WO2002045747A1 (es)
ZA (1) ZA200304415B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
CA2665528C (en) 2006-10-12 2018-01-23 The University Of Tokyo Diagnosis and treatment of cancer using anti-ereg antibody
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
JP5420568B2 (ja) 2008-01-17 2014-02-19 アイアールエム・リミテッド・ライアビリティ・カンパニー 改良された抗ＴｒｋＢ抗体
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CA3053239A1 (en) * 2017-02-17 2018-08-23 George Todaro Use of tgf alpha for the treatment of diseases and disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPH01221326A (ja) * 1988-02-29 1989-09-04 Toyo Jozo Co Ltd 悪性腫瘍細胞障害剤
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
EP0586002B1 (en) 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
CA2261433A1 (en) 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
EP0657175B1 (en) * 1993-12-09 2005-03-02 Centro de Inmunologia Molecular Vaccine comprising human autologous epidermal growth factor and use thereof
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
BR9811264A (pt) * 1997-05-12 2000-07-18 Aphton Corp Composições imunogênicas ao receptor de gastrina/cck-b e métodos para o tratamento de tumores
US20030219380A1 (en) * 1997-11-07 2003-11-27 Annie Fong Method of determining an efficacious dose of a drug
JP2002514573A (ja) * 1998-05-08 2002-05-21 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 能動的なワクチン接種のための組成物および方法
JP2002515511A (ja) * 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
EP1303533A2 (en) * 2000-05-05 2003-04-23 Aphton Corporation Chimeric peptide immunogens, their preparation and use
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas

Also Published As

Publication number Publication date
BR0116010A (pt) 2004-01-06
EA007381B1 (ru) 2006-10-27
ZA200304415B (en) 2004-07-07
CA2431199C (en) 2011-10-04
SI1350521T1 (sl) 2008-12-31
HK1073244A1 (en) 2005-09-30
JP2010150286A (ja) 2010-07-08
EP2005996A3 (en) 2012-01-25
EA200300646A1 (ru) 2003-10-30
EP2005996A2 (en) 2008-12-24
PT1350521E (pt) 2008-11-14
AU2152102A (en) 2002-06-18
EP1350521B1 (en) 2008-08-06
ES2311036T3 (es) 2009-02-01
US20060188497A1 (en) 2006-08-24
CY1108474T1 (el) 2014-04-09
KR20030064416A (ko) 2003-07-31
CN1592636A (zh) 2005-03-09
CU22979A1 (es) 2004-09-09
DK1350521T3 (da) 2008-11-10
DE60135248D1 (de) 2008-09-18
ATE403438T1 (de) 2008-08-15
PE20020695A1 (es) 2002-09-23
EP1350521A1 (en) 2003-10-08
NZ526284A (en) 2004-11-26
AU2002221521B2 (en) 2007-01-04
AR031641A1 (es) 2003-09-24
JP2005519023A (ja) 2005-06-30
UY27058A1 (es) 2002-03-22
US20020160014A1 (en) 2002-10-31
US7744871B2 (en) 2010-06-29
CA2431199A1 (en) 2002-06-13
CN1326566C (zh) 2007-07-18
MY138833A (en) 2009-07-31
WO2002045747A1 (es) 2002-06-13

Similar Documents

Publication Publication Date Title
CY1108474T1 (el) Ανοσοθεραπευτικοι συνδυασμοι για την αγωγη των ογκων
EP1999149A4 (en) ANTI-IGF-1R ANTIBODIES AND USES THEREOF
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
RS20160203A1 (sr) Tretman sa anti-vegf antitelima
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
MY183404A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
MY169308A (en) Treatment of tnf? related disorders
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
MXPA05012832A (es) Punto terminal terapeutico sustituto para inmunoterapia de enfermedad basada en anti-ctla-4.
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
HUP0402656A2 (hu) Sejtterápiás eljárás tumorok kezelésére
MXPA04011550A (es) Tratamiento de carcinoma renal utilizando anticuerpos contra el receptor del factor de crecimiento epidermico.
EA200301097A1 (ru) Иммунотерапевтические комбинации для лечения опухолей, которые сверхэкспрессируют ганглиозиды
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2002074237A3 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002076548A3 (en) Methods and apparatus for treating diseased tissue
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2002077176A3 (en) Aberrantly expressed proteins in laser capture microdissected tumors
EP1499190A4 (en) METHOD FOR THE TREATMENT OF ILL. DISEASES AND LIVER DAMAGES WITH GROWTH HORMONE AND FOXM1B
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders

Legal Events

Date Code Title Description
FG Grant or registration